Stoke Therapeutics, Inc is a biotechnology company based in Bedford, MA that is dedicated to restoring genetic health by developing RNA-based medicines. Their proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), aims to upregulate protein expression from healthy genes to compensate for non-functioning copies of mutated genes. Stoke's initial focus is on diseases characterized by haploinsufficiencies, such as Dravet syndrome, a severe genetic epilepsy. They are committed to developing disease-modifying therapies that address the underlying genetic causes of these severe diseases.
With ongoing clinical studies for the treatment of Dravet syndrome and promising results in other diseases, Stoke Therapeutics is at the forefront of using RNA biology to increase protein output and potentially revolutionize the treatment of severe genetic disorders. Their team is driven by a passion for science and a desire to make a difference in the lives of individuals living with these diseases. Stoke Therapeutics fosters an inclusive and fun work culture, inviting individuals to join their mission and contribute to their groundbreaking research and development efforts.
Generated from the website